Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2101-2117

  Li, Jin Ming ^a   Wang, Yuan Yuan ^a   Zhang, Wei ^a   Su, Hua ^a   Ji, Liang Nian ^a   Mao, Zong Wan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

2 hydroxypropyl cyclodextrin; Folic acid; Gene silencing; Polyethyleneimine; SiRNA carrier; Vascular endothelial growth factor

Indexed keywords

2 HYDROXYPOPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; FOLIC ACID; POLYETHYLENEIMINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; ENDOCYTOSIS; GENE; GENE DELIVERY SYSTEM; GENE SILENCING; GENETIC TRANSFECTION; HETEROZYGOTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PROTEIN EXPRESSION; RNA BINDING; RNA INTERFERENCE; TREATMENT RESPONSE; TUMOR CELL; VEGF GENE; ZETA POTENTIAL;

2-HYDROXYPROPYL-Β-CYCLODEXTRIN; FOLIC ACID; GENE SILENCING; POLYETHYLENEIMINE; SIRNA CARRIER; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CELL SURVIVAL; DRUG CARRIERS; FEMALE; FLOW CYTOMETRY; FOLIC ACID; GENE SILENCING; HELA CELLS; HUMANS; MICE; MICE, NUDE; MOLECULAR WEIGHT; NEOPLASMS, EXPERIMENTAL; POLYETHYLENEIMINE; RNA, SMALL INTERFERING; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878794242     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S42440     Document Type: Article

References (36)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811.
2. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173-184.
3. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129-138.
4. Miele E, Spinelli GP, Miele E, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine. 2012;7:3637-3657.
5. Mintzer MA, Simanek EE. Nonviral vectors for gene delivery. Chem Rev. 2009;109:259-302.
6. Shen M, Gong F, Pang P, et al. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int J Nanomedicine. 2012;7:3319-3332.
7. Yao YD, Sun TM, Huang SY, et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med. 2012;4:130-148.
8. Alameh M, Dejesus D, Jean M, et al. Low molecular weight chitosan nanoparticulate system at low N: P ratio for nontoxic polynucleotide delivery. Int J Nanomedicine. 2012;7:1399-1414.
9. Zhou J, Rossi JJ. Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1. BioDrugs. 2012;26:393-400.
10. Kummitha CM, Malamas AS, Lu ZR. Albumin pre-coating enhances intracellular siRNA delivery of multifunctional amphiphile/siRNA nanoparticles. Int J Nanomedicine. 2012;7:5205-5214.
11. Li JM, Zhao MX, Su H, et al. Multifunctional quantum-dot-based siRNA delivery for HPV18 E6 gene silence and intracellular imaging. Biomaterials. 2011;32:7978-7987.
12. Gao K, Huang L. Nonviral methods for siRNA delivery. Mol Pharm. 2009;6:651-658.
13. de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther. 2008;19:125-132.
14. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114:100-109.
15. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995;92:7297-7301.
16. Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release. 2007;121:64-73.
17. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Control Release. 1999;60:149-160.
18. Fischer D, Li YX, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003;24:1121-1131.
19. Yao H, Ng SS, Tucker WO, et al. The gene transfection efficiency of a folate-PEI600-cyclodextrin nanopolymer. Biomaterials. 2009;30:5793-5803.
20. Li J, Loh XJ. Cyclodextrin-based supramolecular architectures: synthesis, structures, and applications for drug and gene delivery. Adv Drug Deliv Rev. 2008;60:1000-1017.
21. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2004;3:1023-1035.
22. Cryan SA, Holohan A, Donohue R, Darcy R, O'Driscoll CM. Cell transfection with polycationic cyclodextrin vectors. Eur J Pharm Sci. 2004;21:625-633.
23. Pun SH, Bellocq NC, Liu AJ, et al. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug Chem. 2004;15: 831-840.
24. Hu QD, Fan H, Lou WJ, Wang QQ, Tang GP. Polyethylenimine-cyclodextrin-tegafur conjugate shows anti-cancer activity and a potential for gene delivery. J Zhejiang Univ Sci B. 2011;12:720-729.
25. Forrest ML, Gabrielson N, Pack DW. Cyclodextrin-polyethylenimine conjugates for targeted in vitro gene delivery. Biotechnol Bioeng. 2005; 89:416-423.
26. Liang B, He M, Chan C, et al. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat. Biomaterials. 2009;30:4014-4020.
27. Huang HL, Yu H, Tang GP, Wang QQ, Li J. Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-r-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Biomaterials. 2010;31:1830-1838.
28. Park K, Lee MY, Kimb KS, Hahn SK. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine hyaluronic acid conjugate. Biomaterials. 2010;31:5258-5265.
29. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-760.
30. Huang HL, Tang GP, Wang QQ, et al. Two novel non-viral gene delivery vectors: low molecular weight polyethylenimine cross-linked by (2-hydroxypropyl)-b-cyclodextrin or (2-hydroxypropyl)-c-cyclodextrin. Chem Commun. 2006;22:2382-2384.
31. Ogris M, Steinlein P, Kursa M, Mechtler K, Kircheis R, Wagner E. The size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells. Gene Ther. 1998;5:1425-1433.
32. Chollet P, Favrot MC, Hurbin A, Coll JL. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med. 2002;4:84-91.
33. Hwang SJ, Bellocq NC, Davis ME. Effects of structure of β-cyclodextrin-containing polymers on gene delivery. Bioconjug Chem. 2001;12:280-290.
34. Arote R, Hwang SK, Lim HT, et al. The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model. Biomaterials. 2010;31:2435-2445.
35. Sudimach BA, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41:147-162.
36. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer. 2008;8:579-591.